top of page
Executive Spotlights

Harvey J. Berger, M.D., assumes leadership roles as Chairman, President, and CEO at Kojin Therapeutics

Boston, MA, January 03, 2024 (Business Wire) -- Kojin Therapeutics, Inc., focused on cell-state and ferroptosis biology, and innovative drug discovery, has appointed Harvey J. Berger, M.D., as its new Chairman, President, and CEO. A seasoned physician-scientist and entrepreneur with over 35 years of global R&D, corporate, and commercial leadership. Dr. Berger will leverage his significant experience from founding ARIAD Pharmaceuticals where he led the company to become a fully integrated global oncology pioneer. Under his guidance, six groundbreaking medicines for cancer, cardiovascular disease, autoimmune disease, and a cancer-diagnostic blood tests received development and approval.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page